Edition:
United Kingdom

Taro Pharmaceutical Industries Ltd (TARO.N)

TARO.N on New York Stock Exchange

89.46USD
10 Dec 2018
Change (% chg)

$-11.65 (-11.52%)
Prev Close
$101.11
Open
$88.22
Day's High
$89.75
Day's Low
$86.71
Volume
16,668
Avg. Vol
11,406
52-wk High
$121.23
52-wk Low
$86.71

Latest Key Developments (Source: Significant Developments)

Taro Pharmaceutical Industries Reports Q4 EPS $2.17
Thursday, 17 May 2018 

May 17 (Reuters) - Taro Pharmaceutical Industries Ltd ::TARO PROVIDES RESULTS FOR YEAR ENDED MARCH 31, 2018.Q4 EARNINGS PER SHARE $2.17.Q4 SALES $175.2 MILLION.FY EARNINGS PER SHARE $6.18 EXCLUDING ITEMS.  Full Article

Taro Pharmaceutical quarterly earnings per share $1.30
Wednesday, 8 Nov 2017 

Nov 7 (Reuters) - Taro Pharmaceutical Industries Ltd :Quarterly earnings per share $1.30.Quarterly sales $169.9 million.Taro Pharmaceutical Industries Ltd-qtrly ‍shr $1.30​.  Full Article

Taro announces joining of CEO
Friday, 1 Sep 2017 

Sept 2 (Reuters) - Taro Pharmaceutical Industries Ltd :Taro announces joining of CEO.Taro Pharmaceutical Industries Ltd - ‍ Uday Baldota has joined company as its chief executive officer ("CEO") effective August 28, 2017​.Says Uday bBaldota appointed CEO.Taro Pharmaceutical Industries Ltd - Baldota replaces mr. Abhay Gandhi, who served in role of interim chief executive officer since January 1, 2017.Taro Pharmaceutical Industries Ltd - Gandhi will continue in his role as vice chairman of Taro board and as CEO of Sun Pharma North America operations​.  Full Article

Taro reports quarterly net income per ordinary share $1.35
Wednesday, 9 Aug 2017 

Aug 9 (Reuters) - Taro Pharmaceutical Industries Ltd -:Taro provides results for quarter ended June 2017.Quarterly sales $161.3 million.Qtrly net income per ordinary share $1.35.  Full Article

Bellus Health to sell subsidiary Thallion Pharmaceuticals to Taro Pharmaceuticals
Thursday, 16 Mar 2017 

Bellus Health Inc : Press release - Bellus Health announces the sale of subsidiary Thallion Pharmaceuticals to Taro Pharmaceuticals . Bellus Health Inc - deal for total consideration of CA$2.7 million . Bellus Health Inc- in addition will receive a portion of certain post-approval revenues related to shigamab program .Bellus Health Inc - "upfront proceeds from this transaction also meaningfully extend our cash runway to Q4 2018".  Full Article

Taro posts quarterly sales of $220.4 million
Thursday, 9 Feb 2017 

Taro Pharmaceutical Industries Ltd : Taro provides results for December 31, 2016 . Quarterly sales $220.4 million .Taro Pharmaceutical Industries Ltd qtrly net income per ordinary share from continuing operations attributable to taro $3.42.  Full Article